Prilenia Therapeutics
PrivateLast Round
Series B
Apr 12, 2022
Total Funding Raised
$180.5M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Prilenia Therapeutics is a biotechnology company that develops novel therapeutics to slow the progression of neurodegenerative and neurodevelopmental disorders, including Huntington's disease and amyotrophic lateral sclerosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prilenia Therapeutics Comparables
Compare Prilenia Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| QurAlis | 81% | |
| Neurizon Therapeutics Limited | 80% | |
| NeuroSense Therapeutics | 78% |
Prilenia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 12, 2022 | ||||
| Series B | Nov 3, 2021 | ||||
| Series A | Jun 3, 2020 | ||||
| Seed | Sep 1, 2018 |
Key People
Founding team and executive leadership
Prilenia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Series B |
| Forbion | Series B, Series A |
| Amplitude Ventures | Series B |
| Morningside Ventures | Series B, Series A |
| Genworks Health | Series A |
| ALS Investment Fund | Series B |
| Sectoral | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2026
Monthly visitors increased 60% MoM.
- May 1, 2026
Lead candidate pridopidine granted designation in U.S. and EU for HD and ALS.
Recent news
Latest coverage and updates
- hiresSep 8, 2026
Prilenia hired Munschauer as chief medical officer on Sep 8th '26.
- hiresSep 8, 2026
Prilenia hired Frederick (Rick) E. Munschauer III as Chief Medical Officer on Sep 8th '26.
Prilenia Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Prilenia Therapeutics's valuation, stock price, and market status.
Is Prilenia Therapeutics a public or private company?
Prilenia Therapeutics is a private company.
What is the current stock price of Prilenia Therapeutics?
Prilenia Therapeutics is a private company, so its shares have no public market price. Caplight tracks Prilenia Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Prilenia Therapeutics worth (valuation)?
Valuation information for Prilenia Therapeutics is not publicly available.
Can I buy Prilenia Therapeutics stock?
Prilenia Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Prilenia Therapeutics's last funding round?
Prilenia Therapeutics's most recent funding round was Series B on April 12, 2022.
Who are the main investors in Prilenia Therapeutics?
Key investors in Prilenia Therapeutics include Forbion.
Will Prilenia Therapeutics IPO soon?
No public IPO plans have been announced for Prilenia Therapeutics.
How can I track Prilenia Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Prilenia Therapeutics's shares on secondary markets.